Objective. This study examined the association between use of angiotensin converting enzyme inhibitors (ACEIs) and risk of death in elderly patients hospitalized with left ventricular systolic dysfunction (LVSD).
parable to that used in the clinical trials [7, 8] . Despite these obstructive lung disease treated with oxygen, thiamine deimprovements in treatment, rates for hospitalization and, ficiency, amyloidosis, and thyrotoxicosis were excluded from until 1988, deaths due to heart failure have been increasing the cohort. in the United States [2,9,10]. Since LVSD accounts for approximately half of the hospitalized cases of heart failure Data in the elderly, appropriate use of these drugs could result in Medical record personnel at each hospital copied and transreduced mortality in older patients. However, while conmitted each chart for data abstraction by trained nurses and/ siderable evidence suggests that this is the case, many patients or medical record specialists. We assessed inter-rater reliability with LVSD do not receive recommended doses of ACEIs by re-abstraction of a random replicate sample of 35 charts. [11] [12] [13] [14] . For example, a study of over 1600 randomly selected
The kappa estimates of inter-rater reliability for the outcome Medicare beneficiaries hospitalized with heart failure in 1994 measures were 0.81 for the treatment with ACEIs for patients found that only 14% of the patients with LVSD were treated with LVSD to 0.89 for patients who received the target dose with the recommended dose of ACEIs at discharge [14] .
of an ACEI. Although the reasons for the under-treatment of LVSD We abstracted data regarding age, sex, race, length of stay, with ACEIs are not known, factors may include a concern a recorded history of previous myocardial infarction, chronic over adverse drug side effects and the lack of efficacy of obstructive pulmonary disease, bronchitis, emphysema, hyperACEIs in the elderly. However, these concerns may not be tension, and diabetes. To analyze the effects of treatment on warranted. For example, Havraneck et al. [15] showed that patients of advancing age, we divided the cohort into four Medicare patients with LVSD treated with an ACEI at hospital equal age groups: 65-72 years, 73-77 years, 78-82 years, and discharge were less likely to die during the follow-up period.
83 years and older. We abstracted clinical information on However, Havraneck et al. did not examine the possibility patients' history of paroxysmal nocturnal dyspnea (PND), that recommended doses of ACEIs might have adverse dyspnea on exertion (DOE), and orthopnea. Physical findings consequences in older patients. The purpose of this study is abstracted included pedal edema, pulmonary rales, an S 3 to add to the evidence regarding treatment with ACEIs by gallop, and evidence of elevated jugular vein pressure. examining the association between the prescribed dose of an Laboratory information abstracted from the medical record ACEI and subsequent risk of death among heart failure included highest serum creatinine and serum potassium levels, patients with LVSD.
the admission chest radiograph, and the presence of atrial fibrillation on admission. We identified patients with LVSD by looking in the medical
Methods
record for a measure of left ventricular ejection fraction (LVEF) that was obtained during either a previous or the Study design current hospitalization. We also recorded any narrative deThis was a retrospective cohort study of 621 Medicare scription of left ventricular function that included any of the beneficiaries hospitalized for congestive heart failure (CHF) following phrases: systolic dysfunction; dilated cardiodue to LVSD. Sixty-four hospitals in Colorado, Connecticut, myopathy; congestive cardiomyopathy; diffuse or global Georgia, Oklahoma, and Virginia participated in the study. hypokinesis; and description of the ejection fraction (EF) Thirty-two hospitals out of 64 participated voluntarily in a including normal, increased, mildly, moderately, or severely quality improvement trial.
reduced. For previous hospitalization the abstractor looked for a note from a physician mentioning that the patient had Study population a determination of an EF in the past. We defined LVSD as any measured EF equal to or less We randomly selected the medical records of 50 Medicare than 40%. If no information was obtained regarding the EF beneficiaries who had been hospitalized with a principal from the chart, we classified patients as having LVSD if the diagnosis of CHF [International Classification of Diseases, 9th narrative description of the left ventricular function included Revision, Clinical Modification (ICD-9-CM) codes 428 inclusive] the descriptive phrases 'systolic dysfunction', 'dilated cardiofrom each of the study hospitals. If fewer than 50 eligible myopathy', 'congestive cardiomyopathy', or 'diffuse or global patients had been discharged during the enrollment period, hypokinesis', or if the EF was described as reduced in the we evaluated all admissions for CHF. One state used DRG narrative description. Patients with a description of the EF code 127 to identify patients for inclusion in the study.
who were not classified has having LVSD were considered Admissions were identified using the Health Care Financing as patients suffering from a diastolic dysfunction. Administration's (HCFA) MEDPRO file for each state.
We abstracted information regarding medication prePatients were included in the study if they were hospitalized scription and dosage from the physician discharge summary, between the dates of June 30, 1995 and September 30, 1996, nurse discharge summary, and last progress note. The foland were discharged alive from the hospital. Patients were lowing ACEIs by generic and trade names were identified excluded from the cohort if their hospitalization had been and abstracted: benazepril, captopril, enalapril, fosinopril, terminated against medical advice or if they were transferred lisinopril, quinapril, and ramipril. We defined target doses to another hospital. Patients with a diagnosis of valvular heart disease, acute myocardial infarction, cor pulmonale, chronic for individual ACEIs according to those identified in a randomized, controlled clinical trial designed to reduce risk is a weighted sum of selected co-morbidities that were defined 1 Patients may have more than one condition: cor pulmonale by the discharge conditions for the index admission.
or chronic obstructive pulmonary disease requiring home oxygen (n=283), aortic stenosis (n=202), mitral stenosis Follow-up (n=49), end-stage renal disease (n=38), acute MI (n=41), heart failure attributed to thyrotoxicosis (n=3). Follow-up began on the date of discharge for the index hospitalization and continued for one year following discharge. We used the HCFA MEDPRO files to identify subsequent hospitalizations and dates of death.
procedures. When using these two techniques, we used oneyear mortality as a binary variable. However, the survival Statistical analysis analysis allowed us to take into account the time until censoring and our results were unchanged. All analyses were Differences in the proportions of patients within ACEI implemented with the SAS software (SAS Institute Inc., Cary, treatment groups were assessed for statistical significance NC, USA). with a chi-square test [19] . Differences in means across the three groups were tested for significance with ANOVA [20] . We used Kaplan-Meier plots to assess the association between treatment group and mortality [21] . Then, we examined Results the bivariate association between ACEI dose and mortality stratified by patient characteristics with a chi-square test for Between June 30, 1995 and September 30, 1996, we identified 2943 eligible patients who were discharged from the partrends across groups [19] . We used a Cox proportional hazards model to examine the association between mortality and ticipating hospitals with a principal diagnosis of heart failure.
We excluded 2322 (78.9%) of these patients from the analysis ACEI dose, controlling for the other patient characteristics [21] . We entered interaction terms between treatment and all for the following reasons (see Table 1 ): 267 (11.5%) were ineligible after chart review; 599 (25.8%) had secondary causes other variables into these models, including age (as continuous and ordinal variables) to assess the effect of treatment by of heart failure; 584 (25.2%) did not have documented ventricular function; and 659 (28.4%) had left ventricular age. None of these interaction terms was significant at a 5% level with the likelihood ratio test and these interaction terms diastolic dysfunction. Additionally, we excluded patients if they (1) were younger than 65, (2) died during hospitalization, were dropped from the model. Then we implemented a backward elimination in examining whether the withdrawal (3) were transferred to another hospital, (4) had an incomplete chart, and (5) had a stated contraindication to ACEIs noted of the least significant covariate would change the hazard ratio. If this change were 10% or less, this covariate was not in their medical chart (20.7%).
We included 621 patients with LVSD in the analysis. considered as a confounding factor and was removed from the model. These criteria were used until we defined the best The determination of LVSD in patients depended on the documentation of a previous or current EF for 519 (84%). model. We found no co-linearity between variables and no violation of the proportional hazard assumption in our model. For the 102 other (16%) patients we relied on a narrative summary. Among those patients with LVSD and an EF Finally, to account for possible clustering within hospitals, we conducted a second set of analyses with generalized determination, the median of the lowest estimate recorded in the chart was 25% with a 25th-75th intraquartile range estimating equation (GEE) procedures using SAS Proc Genmod. To explore this difference between survival analysis from 20 to 33%.
The mean (SD) age of patients with LVSD was 77.4 (7.0) and GEE procedures, we conducted logistic regression and obtained exactly the same results as we did for the GEE years. Forty-three percent of the patients were female and at target dose for 116 (19%) of the patients. The ACEIs 81% were white. Seventy-seven percent had a history of prescribed included captopril (34%), enalapril (29%), lisinopril heart failure, while 67% were hypertensive (prior history of (25%), quinapril (4%), benazepril (4%), fosinopril (3%), and hypertension or hypertension at admission), and 50% had a ramipril (1%). The percentage of patients at an ACEI target previous myocardial infarction. A history of orthopnea was dose was 11% (95% CI 6-17%) for captopril, 29% (95% CI recorded in the medical record for 42% of the patients 22-37%) for enalapril, 28% (95% CI 20-36%) for lisonopril, with LVSD, DOE for 40%, and PND for 36%. Clinical 50% (95% CI 27-73%) for quinapril, 45% (95% CI 23-68%) examination recorded rales in 85% of patients with LVSD, for benazepril, 10% (95% CI 3-45%) for fosinopril, and 0% edema in 66%, jugular venous distension (JVD) in 50%, and (95% CI 0-0%) for ramipril. The mean (SD) ACEI dose as an S 3 gallop in 30%. We found an admission CXR confirming a proportion of the recommended dose among treated heart failure for 85%. Atrial fibrillation was described in the patients was 47% (50%). Table 2 illustrates the association reports for 25% of the 597 patients who had electrobetween patient characteristics and ACEI dosing. With the cardiograms performed on admission. The median Charlson exception of patients with a previous history of hypertension, co-morbidity index was two.
symptoms of PND, physical findings of S 3 gallop and atrial fibrillation on admission, no patient characteristics were asTreatment of patients with LVSD sociated with ACEI dosing (see Table 2 ). Among the 621 patients with LVSD, 490 (79%) were preWe found no differences in the proportions of patients treated with an ACEI or those treated with the recommended scribed an ACEI at discharge, and ACEIs were prescribed ACEI dose with respect to minimum EF, Charlson co-(reference). Patients in both ACEI treatment categories were morbidity index, chest radiographic confirmation of CHF, or more likely to survive than those not prescribed an ACEI, mean serum potassium (Table 3 ). In contrast, the mean (SD) and those discharged at recommended doses were more likely serum creatinine among patients not prescribed an ACEI to survive than the other patients (Figure 1 ). Risk factors was 1.6 mg% (0.7) compared with 1.4 mg% (0.6) for patients statistically associated (RR) (95% CI) with one-year mortality prescribed an ACEI (P=0.040) ( Table 3) . included: age (continuous) (older patients are of higher risk) Patients not prescribed an ACEI at discharge were more (P=0.008), gender (increased risk for male) [1.30 (1.02-1.65)], likely to be discharged on calcium channel blockers (P= race (increased risk for white) [1.51 (1.05-2.16)], history of 0.001) and hydralazine (P=0.001). Otherwise, the use of heart failure [2.94 (1.88-4.60)], diabetes [1.32 (1.05-1.66)], anticoagulants, beta-blockers, digoxin, diuretics, and nitrates symptoms of PND [0.68 (0.52-0.88)], creatinine (continuous) was comparable among patients discharged on an ACEI and (P<0.001), length of stay (continuous) (P=0.001), and the those not (Table 4) . Finally, there was no difference noted use of hydralazine [1.59 (1.10-2.31)] and nitrate at discharge between those discharged on an ACEI and those not with [1.33 (1.05-1.69)]. respect to the prescription at discharge of a low sodium diet,
We also analyzed the role of patients having received an instructions to weigh daily, the dissemination of smoking ACEI on admission. Among the 621 patients with LVSD, cessation recommendations, and the scheduling of a physician 300 (48%) were on an ACEI when admitted to the hospital. office visit within 14 days of discharge.
Among these patients, 12% received the target dose of the ACEI prescribed. Among patients who were receiving an Survival of patients with LVSD ACEI on admission, at discharge the same dose was prescribed for 45%, an increased dose for 34%, a lower dose Patients diagnosed with LVSD were at high risk of death for 16%, and the ACEI was omitted for 5%. The impact of after discharge. There were 195 deaths during the one-year ACEI dose at discharge on subsequent survival is shown in follow-up period, which comprised 31.4% of the cohort. Figure 2 . There was a strong, graded increase in risk of death as discharge dose decreased from target to no ACEI Bivariate analysis prescribed at discharge among patients who were receiving Among patients not prescribed an ACEI at discharge, 50 the drug on admission. In contrast, no significant trends were died (38%); for patients discharged on an ACEI at less than noted for those patients who were started on an ACEI during target dose, 117 died (31%); and among patients discharged their stay. at target dose, 28 died (24%). Among patients not prescribed an ACEI at discharge, the crude estimated one-year risk ratio Multivariate analysis (RR) of death (95% CI) was 1.58 (1.07-2.33); for patients
The results of the Cox proportional hazard model are predischarged on an ACEI at less than target dose, the risk ratio sented in Table 5 . After controlling for age and other conof death was 1.30 (0.91-1.85); and for those discharged at a recommended ACEI dose, the risk ratio of death was 1.0 founding factors, the risk of death increased as ACEI ..................................................................................................................................................................................................................... (Table 6 ). Age, history of heart failure, PND, creatinine, Charlson co-morbidity index, and length of stay were statistically associated with increased Discussion risk of mortality (Table 5) .
Finally, the results of the secondary analysis with GEE Our findings that elderly patients with LVSD who did not procedures demonstrated that the association between target receive an ACEI have higher mortality rates are consistent dose and one-year mortality is not statistically significant: with earlier studies that led to the development of national when target dose is the reference group, the odds ratio guidelines. The guidelines we used were those available at the time we carried out the study [7, 8] . Recently, new guide-(95% CI) for subtarget is 1.30 (0.85-2.00) (P=0.221), and [24] . In the last decade, clinical trials [7, 8, 25] have factors rather than characteristics of physician care. We demonstrated that appropriate treatment of patients with examined this possibility by: (1) limiting the analysis to those CHF is associated with significant improvements in CHF patients on an ACEI at admission; (2) analyzing changes in symptoms and results in longer survival. A recent meta-ACEI dose over course of hospital care; and (3) controlling analysis including 32 randomized, placebo-controlled trials for multiple co-morbidities. of ACEI use in 7105 patients with symptomatic CHF conThere were other limitations in our study. Firstly, because vincingly showed that treatment with ACEIs reduces the risk hospital participation was voluntary, it is possible that selection of death OR, 0.77: 95% CI, 0.67-0.88. The reduction of total bias occurred. Therefore, the hospitals included in the study mortality was observed for several different ACEIs and was may not be representative of all hospitals in the United States. similar for various subgroups examined (age, sex, etiology, In the study hospitals, patients' demographic and socioand New York Heart Association Class). However, patients economic characteristics could vary systematically or ranwith the lowest EF appeared to have the greatest benefit [5]. domly across hospitals. The prescribing patterns could also A recent study has demonstrated that the use of high dose differ considerably between these hospitals and other hosversus low dose of lisinopril for patients with heart failure pitals. Additionally, it is possible that the study hospitals may reduces risk of death by 8% and hospitalization by 24% [26] . have been more active in developing continuous quality Another recent study showed that among very old patients improvement interventions than non-study hospitals. This the adjusted rate of all-cause mortality was 10% less in ACEI selection bias threatens the external validity and genrecipients compared with patients receiving digoxin (RR, 0.89: eralizability of the study. 95% CI, 0.83-0.95) [27] . Based on these trials, reBecause we did not know if all of the patients were eligible commendations about quality measures for CHF have been for target doses of an ACEI, we cannot determine why the published from a conference consensus [28] .
patients were not prescribed target levels. It may be that Our study demonstrates that elderly patients prescribed some patients who cannot tolerate target doses are more doses of an ACEI at discharge that are lower than those likely to have worse outcomes than those who can tolerate used in randomized, controlled clinical trials (which form the target doses. Additionally, for patients with a terminal illness basis of the clinical guidelines) are at increased risk of death. or those discharged to hospice, the goals of therapy may not We also found increased mortality among patients who were be long-term survival. Because this study is not a clinical not prescribed an ACEI at discharge when compared with trial, the reasons for using a specific medication are not those discharged at subtarget doses of an ACEI. These results randomly distributed. are consistent with the treatment results that CHF clinical
We used an intention-to-treat analysis and assumed that all practice guidelines indicate would occur. Thus, our results patients remained in the same type and dose of treatment as provide additional support for the importance of utilizing prescribed at index discharge. Our analysis does not include evidence-based therapy for elderly patients with CHF.
measures of patient compliance. However, in clinical practice not every patient is discharged from the hospital at target doses Limitations because of the necessary period of dose titration to establish target dose. Therefore, our intention-to-treat analysis could One concern regarding our data is that care was observed have introduced a misclassification bias to the study because over a short time period (i.e. during the course of a hospitalization for heart failure). It is possible that adjustments patients who ultimately receive target levels of an ACEI would
